scholarly journals THE MAGNITUDE OF CARDIOVASCULAR CHANGE IN CIRRHOTIC CARDIOMYOPATHY IN PREDICTING OF HEPATORENAL SYNDROME

2014 ◽  
Vol 63 (12) ◽  
pp. A907
Author(s):  
Parichart Junpaparp ◽  
Bhaskar Purushottam ◽  
Saranya Buppajarntham ◽  
Sherry Pomerantz ◽  
Vincent Figueredo
Keyword(s):  
Hepatorenal Syndrome ◽  
Cirrhotic Cardiomyopathy ◽  
Cardiovascular Change

Hepatorenal Syndrome with Cirrhotic Cardiomyopathy: A Case Series of A New Approach for Re-fractory Patients

2017 ◽  
Vol 6 (2) ◽  
pp. 2344-2348
Author(s):  
Luis Ot醰io Mocarzel ◽  
◽  
D閎ora Balduci Lima ◽  
Davi Gon鏰lves Dias ◽  
Pedro Gemal Lanzieri ◽  
...  
Keyword(s):  
Hepatorenal Syndrome ◽  
Case Series ◽  
Cirrhotic Cardiomyopathy ◽  
New Approach

scholarly journals Hepatorenal Syndrome with Cirrhotic Cardiomyopathy: Case Report and Literature Review

2015 ◽  
Vol 2015 ◽  
pp. 1-4 ◽  
Author(s):  
Luis Mocarzel ◽  
Pedro Lanzieri ◽  
Juliana Nascimento ◽  
Clara Peixoto ◽  
Mário Ribeiro ◽  
...  
Keyword(s):  
Renal Function ◽  
Case Report ◽  
Literature Review ◽  
Speckle Tracking ◽  
Hepatorenal Syndrome ◽  
Systolic Function ◽  
Myocardial Dysfunction ◽  
Normal Ejection Fraction ◽  
Cirrhotic Cardiomyopathy ◽  
Acute Phase Treatment

The hepatorenal syndrome (HRS) is defined as a potentially reversible kidney failure in patients with cirrhosis and ascites. An association of HRS and cirrhotic cardiomyopathy has been reported recently, but there are no result studies about the use of positive inotropes as part of the acute phase treatment. We report the case of a patient diagnosed with HRS, with high levels of NT pro-BNP, but with normal ejection fraction of the left ventricle, which showed abnormalities in systolic function through speckle tracking in echocardiography, reversible after the infusion of dobutamine. The patient showed clinical and laboratory improvement of his renal function after the infusion of dobutamine. Clinical studies are needed on HRS therapeutic approach taking into account the myocardial dysfunction as a major contributing factor to renal dysfunction.

scholarly journals Clinical Manifestations of Portal Hypertension

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Said A. Al-Busafi ◽  
Julia McNabb-Baltar ◽  
Amanda Farag ◽  
Nir Hilzenrat
Keyword(s):  
Portal Hypertension ◽  
Spontaneous Bacterial Peritonitis ◽  
Hepatorenal Syndrome ◽  
Clinical Manifestations ◽  
Hepatopulmonary Syndrome ◽  
Portal Hypertensive Gastropathy ◽  
Portopulmonary Hypertension ◽  
Cirrhotic Cardiomyopathy ◽  
Gastroesophageal Varices ◽  
Bacterial Peritonitis

The portal hypertension is responsible for many of the manifestations of liver cirrhosis. Some of these complications are the direct consequences of portal hypertension, such as gastrointestinal bleeding from ruptured gastroesophageal varices and from portal hypertensive gastropathy and colopathy, ascites and hepatorenal syndrome, and hypersplenism. In other complications, portal hypertension plays a key role, although it is not the only pathophysiological factor in their development. These include spontaneous bacterial peritonitis, hepatic encephalopathy, cirrhotic cardiomyopathy, hepatopulmonary syndrome, and portopulmonary hypertension.

scholarly journals Cirrhotic Cardiomyopathy: Another Case of a Successful Approach to Treatment of Hepatorenal Syndrome

2016 ◽  
Vol 10 (3) ◽  
pp. 531-537 ◽  
Author(s):  
Luis Otávio Mocarzel ◽  
Jessica Bicca ◽  
Luiza Jarske ◽  
Thamires Oliveira ◽  
Pedro Lanzieri ◽  
...  
Keyword(s):  
Renal Function ◽  
Speckle Tracking ◽  
Hepatorenal Syndrome ◽  
Speckle Tracking Echocardiography ◽  
Systolic Function ◽  
Myocardial Dysfunction ◽  
Type I ◽  
Cirrhotic Cardiomyopathy ◽  
Current Therapies ◽  
Successful Approach

Hepatorenal syndrome (HRS) is defined as a failure of renal function, potentially reversible, in patients with liver cirrhosis and ascites. Recently, a component of cardiomyopathy associated with HRS was described, but the use of positive inotropic medicine as part of the treatment of the acute phase has not been extensively evaluated. We report a second case in our hospital of a patient with HRS type I without previous heart disease, with secondary hemodynamic decompensation due to liver disease, in which the abnormalities in systolic function by speckle-tracking echocardiography were observed and could be reversed by the use of inotropes. After partial response to current therapies, the patient presented a clinical and laboratorial response with improvement of renal function after infusion of dobutamine. Clinical studies are needed for the therapy approach to HRS taking into account myocardial dysfunction as a major contributing factor for renal dysfunction.

Sign in / Sign up

Export Citation Format

Share Document